JIAHUI WANG^1,#, HONGCHENG GE^2,3,#, ZHENGYUAN YU^1,*, LINGZHI WU^1,*

Oncology Research, Vol.33, No.5, pp. 1033-1054, 2025, DOI:10.32604/or.2024.058256 - 18 April 2025

Abstract Lung cancer is a common cause of cancer-related death globally. The majority of lung cancer patients initially benefit from chemotherapy and immunotherapy. However, as the treatment cycle progresses and the disease evolves, the emergence of acquired resistance leads to treatment failure. Many researches have shown that non-coding RNAs (ncRNAs) not only influence lung cancer progression but also act as potential mediators of immunotherapy and chemotherapy resistance in lung cancer, mediating drug resistance by regulating multiple targets and pathways. In addition, the regulation of immune response by ncRNAs is dualistic, forming a microenvironment for inhibits/promotes More >

Hongjuan Guo¹, Dan Liu^1,2, Ruyu Yan^1,2, Tianjing Zhang³, Kecheng Zhou^1,2,*, Minxia Liu^1,*

BIOCELL, Vol.49, No.3, pp. 483-502, 2025, DOI:10.32604/biocell.2025.062143 - 31 March 2025

Abstract Objectives: Non-small cell lung cancer (NSCLC) represents a formidable malignancy characterized by its marked metastatic potential and intrinsic resistance to therapeutic interventions. The identification of potential biomarkers delineating the progression and metastatic cascade of NSCLC assumes paramount importance in fostering advancements toward enhanced patient outcomes and prognostic stratification. Methods: The expression level of the actin-related protein 2/3 complex; subunit 1A (ARPC1A) in NSCLC was evaluated using The Cancer Genome Atlas (TCGA) and Gene Expression Profiling Interactive Analysis (GEPIA) databases; along with the LinkedOmics database for co-expression genes. Further verification of ARPC1A expression in normal lung cells… More >

JIAHENG WEI¹, LIANGMING ZHU^2,*

Oncology Research, Vol.33, No.4, pp. 863-872, 2025, DOI:10.32604/or.2024.054201 - 19 March 2025

Abstract Lung cancer is one of the main causes of cancer-related deaths globally, with non-small cell lung cancer (NSCLC) being the most prevalent histological subtype of lung cancer. Glutathione peroxidase 4 (GPX4) is a crucial antioxidant enzyme that plays a role in regulating ferroptosis. It is also involved in a wide variety of biological processes, such as tumor cell growth invasion, migration, and resistance to drugs. This study comprehensively examined the role of GPX4 in NSCLC and investigated the clinical feasibility of targeting GPX4 for NSCLC treatment. We discovered that GPX4 influences the progression of NSCLC More >

HENG ZHANG^1,#, XIAO YANG^2,#, YUJIN GUO³, HAIBO ZHAO⁴, PEI JIANG^5,*, QING-QING YU^3,*

Oncology Research, Vol.33, No.4, pp. 837-849, 2025, DOI:10.32604/or.2024.053882 - 19 March 2025

Abstract As living conditions improve and diagnostic capabilities advance, the incidence of tumors has increased, with cancer becoming a leading cause of death worldwide. Surgery, chemotherapy, and radiotherapy are the most common treatments. Despite advances in treatment options, chemotherapy remains a routine first-line treatment for most tumors. Due to the continuous and extensive use of chemotherapy drugs, tumor resistance often develops, becoming a significant cause of treatment failure and poor prognosis. Recent research has increasingly focused on how long stranded non-coding RNAs (LncRNAs) influence the development of malignant tumors and drug resistance by regulating gene expression More >

GAMALELDIN I. HARISA^1,*, RIYAD F. ALZHRANI¹, ABDULRAHMAN A. ALLUHAIDAN¹, SULTAN M. ALAMRI¹, AHMED H. BAKHEIT², HANADI H. ASIRI², SABRY M. ATTIA³

Oncology Research, Vol.33, No.2, pp. 477-492, 2025, DOI:10.32604/or.2024.053337 - 16 January 2025

Abstract Background: Hepatocellular carcinoma (HCC) is a health problem due to multi-drug resistance (MDR). Codelivery of multiple oncotherapy in one cargo as chimeric cancer therapy (CCT) is suggested as a solution for MDR. This study aims to engineer chitosan-coated nanostructure lipid carriers (NLCs) loaded with gefitinib (GF) and simvastatin (SV) as CCT for HCC. Methods: Both GF and SV-loaded nanostructure lipids carriers (GFSVNLC) and chitosan-capped GF and SV-loaded nanostructure lipids carriers (CGFSVNLC) formulations were assembled by top-down techniques. Moreover, particle size (PS), zeta potential (ZP), and polydispersity index (PDI) were measured by Zetasizer. The biosafety of… More > Graphic Abstract

YUQIN YIN^1,2,#, YU WU^1,#, HONGLIANG HUANG^1,2, YINGYING DUAN^1,2, ZHONGWEN YUAN^1,2, LIHUI CAO^1,2, JINJIN YING^1,2, YONGHENG ZHOU^3,*, SENLING FENG^1,2,*

Oncology Research, Vol.32, No.12, pp. 1891-1902, 2024, DOI:10.32604/or.2024.048778 - 13 November 2024

Abstract Background: Polymethoxylated flavones (PMFs) are compounds present in citrus peels and other Rutaceae plants, which exhibit diverse biological activities, including robust antitumor and antioxidant effects. However, the mechanism of PMFs in reversing drug resistance to colon cancer remains unknown. In the present study, we aimed to investigate the potential connection between the aerobic glycolysis-ROS-autophagy signaling axis and the reversal of PTX resistance in colon cancer by PMFs. Methods: MTT Cell viability assay and colony formation assay were used to investigate the effect of PMFs combined with PTX in reversing HCT8/T cell resistance ex vivo; the mRNA… More > Graphic Abstract

XIAOXIAO HE¹, XUEQING ZHOU², JINPENG ZHANG², MINGFEI ZHANG², DANHONG ZENG², HENG ZHANG¹, SHUCAI YANG^2,*

BIOCELL, Vol.48, No.9, pp. 1331-1341, 2024, DOI:10.32604/biocell.2024.052625 - 04 September 2024

Abstract Objectives: This investigation aimed to elucidate the inhibitory impact of apatinib on the multidrug resistance of liver cancer both in vivo and in vitro. Methods: To establish a Hep3B/5-Fu resistant cell line, 5-Fu concentrations were gradually increased in the culture media. Hep3B/5-Fu cells drug resistance and its alleviation by apatinib were confirmed via flow cytometry and Cell Counting Kit 8 (CCK8) test. Further, Nuclear factor kappa B (NF-κB) siRNA was transfected into Hep3B/5-Fu cells to assess alterations in the expression of multidrug resistance (MDR)-related genes and proteins. Nude mice were injected with Hep3B/5-Fu cells to establish subcutaneous… More >

KUN FENG^1,#, HAO PENG^2,#, QINGPENG LV¹, YEWEI ZHANG^1,*

Oncology Research, Vol.32, No.6, pp. 1063-1078, 2024, DOI:10.32604/or.2024.047078 - 23 May 2024

Abstract Hepatocellular carcinoma (HCC) is a malignancy known for its unfavorable prognosis. The dysregulation of the tumor microenvironment (TME) can affect the sensitivity to immunotherapy or chemotherapy, leading to treatment failure. The elucidation of PHLDA2’s involvement in HCC is imperative, and the clinical value of PHLDA2 is also underestimated. Here, bioinformatics analysis was performed in multiple cohorts to explore the phenotype and mechanism through which PHLDA2 may affect the progression of HCC. Then, the expression and function of PHLDA2 were examined via the qRT-PCR, Western Blot, and MTT assays. Our findings indicate a substantial upregulation of… More >

EFFAT ALEMZADEH¹, LEILA ALLAHQOLI², AFROOZ MAZIDIMORADI³, ESMAT ALEMZADEH^1,4, FAHIMEH GHASEMI^4,5, HAMID SALEHINIYA⁶, IBRAHIM ALKATOUT^7,*

Oncology Research, Vol.32, No.5, pp. 831-847, 2024, DOI:10.32604/or.2024.031006 - 23 April 2024

Abstract Ovarian cancer is among the most lethal gynecological cancers, primarily due to the lack of specific symptoms leading to an advanced-stage diagnosis and resistance to chemotherapy. Drug resistance (DR) poses the most significant challenge in treating patients with existing drugs. The Food and Drug Administration (FDA) has recently approved three new therapeutic drugs, including two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and niraparib) and one vascular endothelial growth factor (VEGF) inhibitor (bevacizumab) for maintenance therapy. However, resistance to these new drugs has emerged. Therefore, understanding the mechanisms of DR and exploring new approaches to overcome More >

KEGANG JIA^1,#, YAWEI WANG^2,#, QI CAO^3,*, YOUYU WANG^1,*

Oncology Research, Vol.32, No.2, pp. 409-419, 2024, DOI:10.32604/or.2023.042863 - 28 December 2023

Abstract Background: Lung cancer is the most prevalent cancer diagnosis and the leading cause of cancer death worldwide. Therapeutic failure in lung cancer (LUAD) is heavily influenced by drug resistance. This challenge stems from the diverse cell populations within the tumor, each having unique genetic, epigenetic, and phenotypic profiles. Such variations lead to varied therapeutic responses, thereby contributing to tumor relapse and disease progression. Methods: The Genomics of Drug Sensitivity in Cancer (GDSC) database was used in this investigation to obtain the mRNA expression dataset, genomic mutation profile, and drug sensitivity information of NSCLS. Machine Learning… More >